ROCO
3218
Market cap353mUSD
Oct 08, Last price
133.00TWD
1D
-0.37%
1Q
-5.67%
Jan 2017
564.00%
IPO
302.42%
Name
Universal Vision Biotechnology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Universal Vision Biotechnology Co., Ltd., established in 1992 and based in Taipei, Taiwan, manages a network of eye care clinics across both Taiwan and China. The company delivers a comprehensive range of ophthalmic services, encompassing advanced surgical interventions and treatments for various ocular conditions. Its surgical specialties include laser vision correction for common refractive errors such as myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related vision decline). They also perform intraocular lens procedures for presbyopia and cataracts, employing advanced techniques like phacoemulsification and femtosecond laser surgery. Beyond surgical solutions, Universal Vision addresses a wide spectrum of eye health concerns, offering services for myopia control, dry eye syndrome, retinal detachment, macular degeneration, strabismus (crossed eyes), amblyopia (lazy eye), and numerous other ophthalmic ailments. The company further provides a diverse array of vision products and optical aids, including various eyeglass frames, specialized multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, and both conventional and colored contact lenses. Nutritional eye supplements are also available. Additional offerings include oculoplastic and micro cosmetic eye surgery, alongside bespoke aesthetic medicine consultations. Furthermore, Universal Vision engages in optometric services, hospital administration, technical advisory roles, and the distribution and rental of medical equipment.
Key people
Chief Technology Officer, Director · since 2011
Kenneth Lu
General Manager · since 2010
Su-Ping Lien
Head of Corporate Governance, Manager of Sustainable Development Office · since 2022
Yu-Chiao Sun
Head of Finance & Accounting · since 2022
Director · since 2024
Tsan-Der Chou
Director · since 2018
Chairman of the Board · since 2010
Su-Hei Weng
Director · since 2018
Independent Director · since 2024
Independent Director · since 2012
Independent Director · since 2018
Independent Director · since 2021
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||